Evidence map›Paper›PMID 40198613›Full record

ArticleOncoimmunology2025

Novel immunodominant neoepitope in a KPC mouse model of pancreatic cancer allowing identification of tumor-specific T cells.

Maria Antsiferova, Marco Berrera, Anne-Claire Zagdoun, Maha Raauf, Thuy Trinh Nguyen, Claudio Murgia, Birte Appelt, Christine Trumpfheller, Stephan Gasser, Sylvain Pilet and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maria AntsiferovaCancer Immunotherapy, Oncology Discovery, Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.
Marco BerreraPredictive Modelling and Data Analytics, Pharmaceutical Sciences, Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
Anne-Claire ZagdounCancer Immunotherapy, Oncology Discovery, Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.
Maha RaaufCancer Immunotherapy, Oncology Discovery, Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.
Thuy Trinh NguyenCancer Immunotherapy, Oncology Discovery, Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.
Claudio MurgiaCancer Immunotherapy, Oncology Discovery, Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.
Birte AppeltCancer Immunotherapy, Oncology Discovery, Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.
Christine TrumpfhellerCancer Immunotherapy, Oncology Discovery, Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.
Stephan GasserCancer Immunotherapy, Oncology Discovery, Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.
Sylvain PiletCancer Immunotherapy, Oncology Discovery, Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.
Valeria NicoliniCancer Immunotherapy, Oncology Discovery, Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.
Ines Grazina de MatosCancer Immunotherapy, Oncology Discovery, Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 4662 KPC model is one of the most widely used mouse models of pancreatic cancer. It represents an excluded immune phenotype and closely recapitulates the pathophysiology of pancreatic cancer in humans. We set out to identify the endogenous neoepitopes present in 4662 cells. By combining whole-exome and RNA-sequencing and a bioinformatic neoantigen prediction pipeline, we have identified 15 potential candidate neoantigen epitopes. Ten more highly expressed were selected for validation in an in vivo vaccination study with 4662-tumor bearing mice. The

Indexed as

Antigens, NeoplasmCD8-Positive T-LymphocytesEpitopes, T-LymphocyteImmunodominant EpitopesPancreatic NeoplasmsAnimalsCancer VaccinesCell Line, TumorDisease Models, AnimalHumansMiceAntigens, NeoplasmCancer VaccinesEpitopes, T-LymphocyteImmunodominant EpitopesCancer neoantigenKPC modelneoepitopepancreatic cancertumor-specific T cells

Identifiers

PMID40198613
PMCPMC11988233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.